Guidelines for the Economic Evaluation of Vaccination Programs in Canada

Author(s)

Sander B1, Krahn M1, Prosser LA2, Bryan S3, Brouwer W4, Jit M5, Lee K6, Naus M7, Ozawa S8, Lathia N9, Yeung MW10, Nam A11, Tuite A11, House A12, Tunis M12
1University of Toronto, Toronto, ON, Canada, 2University of Michigan, Ann Arbor, MI, USA, 3University of British Columbia, Vancouver, BC, Canada, 4Erasmus School of Health Policy & Management, Rotterdam, Netherlands, 5London School of Hygiene & Tropical Medicine, London, UK, 6Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada, 7British Columbia Centre for Disease Control, Vancouver, BC, Canada, 8University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 9Toronto, ON, Canada, 10Public Health Agency of Canada, Ottawa , Canada, 11Public Health Agency of Canada, Toronto, ON, Canada, 12Public Health Agency of Canada, Ottawa, ON, Canada

OBJECTIVES:

Canada’s National Advisory Committee on Immunization (NACI) makes recommendations on the use of human vaccines. Traditionally, NACI reviewed vaccine characteristics and disease burden. With its expanded mandate, NACI now considers cost-effectiveness via economic evaluations; thus, warranting guidelines. Existing guidelines are either not specific to the universal healthcare context, or not specific to vaccination programs.

METHODS:

A task group was convened to develop NACI’s Guidelines for the Economic Evaluation of Vaccination Programs in Canada. The group comprised of international experts in health economics, guidelines development, childhood health and infectious diseases modelling, as well as federal/ provincial/ territorial liaisons. Recommendations were made through consensus, informed by literature reviews, consultations and review by government partners, decision-makers, academics, health technology assessment agencies, industry, patient groups, and others.

RESULTS:

The guidelines consist of 15 chapters on conducting economic evaluations (i.e., from conceptualizing the decision problem to reporting). Unlike other health technologies, vaccines have the potential to affect both vaccinated and unvaccinated individuals. The guidelines detail population-level impacts including externalities (e.g., herd immunity, age-shifting of disease) and spillover effects. They also discuss equity considerations and non-health impacts of vaccines such as to productivity, consumption and education. An Impact Inventory adapted from the United States is available for users to consider the range of impacts. The guidelines recommend two perspectives as reference cases: publicly funded health system and societal.

CONCLUSIONS:

NACI’s first edition guidelines fill an unmet need and promote standardized economic evaluations. They advocate for transparency, allowing evidence to be used across different jurisdictions, even beyond Canada. They also encourage users to explore emerging methods such as for societal perspective analyses and equity-informed analyses. An outstanding gap to be addressed in subsequent iterations is incorporating Indigenous considerations.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

EE211

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×